Clinical Trial Update: Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates cabazitaxel, carboplatin, and cetrelimab with or without niraparib for aggressive variant metastatic prostate cancer; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer
• Prostate Neuroendocrine Carcinoma
• Prostate Small Cell Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Cabazitaxel (Jevtana) (cabazitaxel)
• Cetrelimab
• Niraparib (Niraparib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING